Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ziprasidone mesylate
Drug ID BADD_D02391
Description Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior.[A190525] These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers.[A190525] Luckily, several treatment options for psychotic disorders have been introduced to market since the realization of chlorpromazine's antipsychotic properties in 1952.[A190525] Second generation antipsychotics (commonly referred to as atypical antipsychotics) include [clozapine], [quetiapine], [olanzapine], [aripiprazole] and [ziprasidone] among others, and are generally thought to be as efficacious as first generation antipsychotics but differ in their adverse effect profiles.[A190525,A190534] First generation antipsychotics are associated with extrapyramidal adverse effects while atypical antipsychotics are linked to weight gain, impaired glucose tolerance and metabolic syndrome.[A190534,A190537] Ziprasidone is used to treat schizophrenia and bipolar disorder.[A180748] It can effectively reduce the rate and time of relapses in schizophrenia, and can be used to treat manic episodes in bipolar disorder although the mechanism of action is unknown.[A180748] Although ziprasidone is classified as an atypical antipsychotic, it appears to have a lower incidence of metabolic adverse effects compared to other medications in the same class.[A190525]
Indications and Usage For the treatment of schizophrenia and related psychotic disorders.
Marketing Status Prescription; Discontinued
ATC Code N05AE04
DrugBank ID DB00246
KEGG ID D02100
MeSH ID C092292
PubChem ID 154068
TTD Drug ID D0R1JV
NDC Product Code 72266-160; 50090-4540; 0049-3920; 43598-848; 51662-1564; 68083-340; 0049-1203
Synonyms ziprasidone | ziprazidone | 5-(2-(4-(3-benzisothiazolyl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one | ziprasidone hydrochloride | CP 88059-01 | CP-88,059-1 | CP-88,059-01 | ziprasidone hydrochloride, monohydrate | Geodon | CP 88059 | CP-88,059
Chemical Information
Molecular Formula C22H25ClN4O4S2
CAS Registry Number 185021-64-1
SMILES CS(=O)(=O)O.C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatomegaly09.01.05.001--Not Available
Hostility19.05.01.003--Not Available
Hyperchloraemia14.05.08.001--Not Available
Hypercholesterolaemia14.08.01.001--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkalaemia14.05.03.001--
Hyperkinesia17.01.02.008--Not Available
Hyperreflexia17.02.01.002--Not Available
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hyperthyroidism05.02.02.001; 14.11.01.011--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hyperuricaemia14.09.01.003--
Hypoaesthesia17.02.06.023--Not Available
Hypocalcaemia14.04.01.004--
Hypochloraemia14.05.08.003--Not Available
Hypocholesterolaemia14.08.04.013--Not Available
Hypochromic anaemia01.03.02.004--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypokalaemia14.05.03.002--
Hypokinesia17.01.02.009--Not Available
Hypomagnesaemia14.04.02.001--
Hypomania19.16.02.001--Not Available
Hyponatraemia14.05.04.002--
Hypoproteinaemia14.10.01.003; 09.01.02.004--Not Available
Hypothermia12.05.03.001; 08.05.01.003--
Hypothyroidism14.11.01.012; 05.02.03.001--
Hypotonia17.05.02.002; 15.05.04.008--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 8 Pages